Online English Summarizer tool, free and accurate!
We provide an up-to-date meta-analysis of trials showing
the benefits of SGLT2i for the reduction of cardiorenal mor-
bidity and mortality in individuals living with HF or CKD
and we reappraise the comparison of SGLT2i in people with
T2D as well.Additionally, the significant but modest reduction in
non-fatal MI of 10% with SGLT2i remains not significantly
different from the 6%-point estimate reduction associated
with GLP-1 RA, which itself is not significant.In the current analy-
sis, however, the risk reduction associated with SGLT2iWe believe, therefore, that the existing CCS
guidelines recommending use of an SGLT2i in adults with
CKD (UACR>20 mg/mmol, eGFR>=25 mL/min/1.73m2)
to reduce the composite of a significant decline in eGFR,
progression to end-stage kidney disease or death due to kid-
ney disease, all-cause and CV mortality, non-fatal MI, and
hospitalization for HF remain largely unchanged although
a slightly lower eGFR of 20 mL/min/1.73m2 would be con-
sidered reasonable.Finally, it is impor-
tant to note that the prior CCS cardiorenal guideline com-
mittee did not feel that recommendations regarding either
HF or CKD protection using GLP1-RA were warranted in
the absence of published, dedicated trials in these popula-
tions.The EMPA-Kidney trial is unique in adding informa-
tion to participants with CKD defined by an eGFR of at
least 20 mL/min/1.73m2 but less than 45 mL/min/1.73m2
of body-surface area, or who had an eGFR of at least 45
mL/min/1.73m2 but less than 90 mL/min/1.73m2 with a
urinary albumin-to-creatinine ratio (with albumin mea-
sured in milligrams and creatinine measured in grams) of
at least 200.The effect on
the combined outcome of CV mortality or HF hospitaliza-
tion also remained unchanged (25% reduction) despite the
data from two additional trials (DELIVER and EMPULSE,
Fig.
We provide an up-to-date meta-analysis of trials showing
the benefits of SGLT2i for the reduction of cardiorenal mor-
bidity and mortality in individuals living with HF or CKD
and we reappraise the comparison of SGLT2i in people with
T2D as well. In people with HF, the results show benefits
across the spectrum of EF with reductions in the composite
endpoint of CV Death or hospitalization for HF in the range
of 21 to 25% and for reduction of hospitalization for HF
in the range of 31 to 26%. However, despite the additional
DELIVER trial data, reduction in all cause or CV mortality
and reduction in the renal composite endpoint remain evi-
dent only in the HFrEF population (Fig. 2 and Supplemental
Figures S9 – S16).
The EMPA-Kidney trial is unique in adding informa-
tion to participants with CKD defined by an eGFR of at
least 20 mL/min/1.73m2 but less than 45 mL/min/1.73m2
of body-surface area, or who had an eGFR of at least 45
mL/min/1.73m2 but less than 90 mL/min/1.73m2 with a
urinary albumin-to-creatinine ratio (with albumin mea-
sured in milligrams and creatinine measured in grams) of
at least 200. However, the report does not provide infor-
mation regarding the primary or individual endpoints for
these two disparate groups of participants. Subset analyses
stratified by eGFR or by albuminuria separately are, strictly
speaking, not heterogeneous but the report suggests that
benefits are seen largely in participants with higher levels
of proteinuria. We believe, therefore, that the existing CCS
guidelines recommending use of an SGLT2i in adults with
CKD (UACR>20 mg/mmol, eGFR≥25 mL/min/1.73m2)
to reduce the composite of a significant decline in eGFR,
progression to end-stage kidney disease or death due to kid-
ney disease, all-cause and CV mortality, non-fatal MI, and
hospitalization for HF remain largely unchanged although
a slightly lower eGFR of 20 mL/min/1.73m2 would be con-
sidered reasonable. In this group, the endpoint of non-fatal
stroke shows a point estimate reduction of 22% but this
remains non-significant in the new analysis even with the
new trial (Fig. 2 and Supplemental Figure S14). The effect on
the combined outcome of CV mortality or HF hospitaliza-
tion also remained unchanged (25% reduction) despite the
data from two additional trials (DELIVER and EMPULSE,
Fig. 2 and Supplemental Figure S11).
In individuals living with T2D with ASCVD or with mul-
tiple risk factors for ASCVD, the recommendations regard-
ing the use of either SGLT2i or GLP-1 RA for reduction of
all-cause or CV death or MACE are substantiated. Similarly,
the inclusion of new trial data does not alter our prior con-
clusion that there is a strong signal for the reduction of non-
fatal stroke associated with the GLP-1 but not the SGLT2i
class. Additionally, the significant but modest reduction in
non-fatal MI of 10% with SGLT2i remains not significantly
different from the 6%-point estimate reduction associated
with GLP-1 RA, which itself is not significant. Accordingly,
the new data still support the reticence of the CCS cardiore-
nal guideline to make any recommendations regarding the
reduction of non-fatal MI using SGLT2i. Finally, it is impor-
tant to note that the prior CCS cardiorenal guideline com-
mittee did not feel that recommendations regarding either
HF or CKD protection using GLP1-RA were warranted in
the absence of published, dedicated trials in these popula-
tions. In the population of people with T2D, the signal for
the reduction in the renal composite endpoint of 22% asso-
ciated with GLP-1 RA use was inferior to the 35% reduction
associated with the use of SGLT2i. In the current analy-
sis, however, the risk reduction associated with SGLT2i
Summarize English and Arabic text using the statistical algorithm and sorting sentences based on its importance
You can download the summary result with one of any available formats such as PDF,DOCX and TXT
ٌYou can share the summary link easily, we keep the summary on the website for future reference,except for private summaries.
We are working on adding new features to make summarization more easy and accurate
a. Expansion of product offerings - Amazon should expand its product offerings in the Kuwaiti market...
عد القدس من أعرق وأقدم المدن في التاريخ ولكن اختلف العلماء على تاريخ القدس فمنهم من يقول إنها ٣٨ ألف...
1. القطاع الاقتصادي: - تشوه المنافسة: عندما تُعطى الشركات الكبيرة المزايا غير العادلة وتحظى بامتي...
ما هي التنمية املستدامة ؟ التنمية المستدامة هي نموذج شامل لألمم المتحددة تدم توصديف مفهدوم التنميدة ...
The conditions for gel filtration chromatography can vary depending on the specific application and ...
قرائن على دور الامام الرضا العلمي لنرى بعض القرائن على دوره العلمي المتميز الذي استحق بواسطته ان يق...
براه الله لرعيته عادلا وفيا ، لا يلقى المنكر بالمعروف ولا المعروف بالمنكر ، يجزى على الإساءة إساءة و...
Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy. The design o...
اريد تلخيص لشرح المسرحية في حدود ٢٥٠ كلمة : النص ادناه شرح مسرحية البخيل: تبدأ أحداث المسرحية مع لا...
يعتبر التعليم نشاطا اجتماعيا على جانب كبير من الأهمية كونه يسعى إلى المشاركة في تكوين شخصية المتعلم ...
.هداف كتابة التقارير : إن الهدف الأساسي لكتابة التقارير هو نقل المعلومات وفي بعض الحالات تستخدم التق...
Preserving Documentation Integrity Ensuring the integrity of HR documentation is important to help p...